High-dose treosulfan in conditioning prior to hematopoietic stem cell transplantation

Bibliography

• Ljungman P, Urbano-Ispizua A, Cavazanna-Calvo M, Allogeneic and autologous transplantation for haematological diseases, solid tumors and immune disorders: definitions and current practice in Europe. Bone Marrow Transplant 2006;37:439-49
   PubMed Web of Science ®Google Scholar
• Pasquini MS, Wang Z. CIBMTR summary slides: current uses and outcomes of hematopoietic stem cell transplantation 2009. CIBMTR Newsl 2009;15:7-11
   Google Scholar
• Alyea EP, Kim HT, Ho V, Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic stem cell transplantation for patients older than 50 years of age. Blood 2005;105:1810-14
   PubMed Web of Science ®Google Scholar
• Landfried K, Wolff D, Holler E. Pathophysiology and management of graft-versus-host disease in the era of reduced-intensity conditioning. Curr Opin Oncol 2009;21(Suppl 1):S29-41
   PubMedGoogle Scholar
• Satwani P, Cooper N, Rao K, Reduced intensity conditioning and allogeneic stem cell transplantation in childhood malignant and nonmalignant diseases. Bone Marrow Transplant 2008;41:173-82
   PubMed Web of Science ®Google Scholar
• Hilger RA, Harstrick A, Eberhardt W, Clinical pharmacokinetics of intravenous treosulfan in patients with advanced solid tumors. Cancer Chemother Pharmacol 1998;42:99-104
   PubMed Web of Science ®Google Scholar
• Schuelen ME, Hilger RA, Oberhoff C, Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies. Clin Cancer Res 2000;6:4209-16
   PubMed Web of Science ®Google Scholar
• Gropp M, Meier W, Hepp H. Treosulfan as an effective second-line therapy in ovarian cancer. Gynecol Oncol 1998;71:94-8
   PubMed Web of Science ®Google Scholar
• Spieth K, Kaufmann R, Gille J. Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study. Cancer Chemother Pharmacol 2003;52:377-82
   PubMed Web of Science ®Google Scholar
• Treosulfan Injection (Medac UK)-Summary of Product Characteristics (SPC)-electronic Medicines Compendium (eMC). Available from: http://emc.medicines.org.uk/medicine/6431/SPC/Treosulfan+ Injection++(medac+UK)/ [Last accessed 4 May 2010]
   Google Scholar
• Treosulfan Capsules 250 mg (Medac UK)-Summary of Product Characteristics (SPC)-electronic Medicines Compendium (eMC). Available from: http://emc.medicines.org.uk/medicine/6426/SPC/Treosulfan+ Capsules+250+mg+++(Medac+UK)/ [Last accessed 4 May 2010]
   Google Scholar
• Wachowiak J, Chybicka A, Boruczkowski D, Intravenous treosulfan in conditioning regimen for allogeneic HSCT from MSD in children with high risk of toxic complications related to conventional preparative. Bone Marrow Transplant 2002;30(Suppl 1) S12
   Google Scholar
• Casper J, Knauf K, Kiefer T, Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation. Blood 2004;103:725-31
   PubMed Web of Science ®Google Scholar
• Beelen DW, Trenschel R, Casper J, Conditioning. Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications. Bone Marrow Transplant 2005;35:233-41
   PubMed Web of Science ®Google Scholar
• Cutting R, Mirelman A, Vora A. Treosulphan as an alternative to busulfan for myeloablative conditioning in paediatric allogeneic transplantation. Br J Haematol 2008;143:748-51
   PubMed Web of Science ®Google Scholar
• Sauer M, Zeidler C, Meissner B, Substitution of cyclophosphamide and busulfan by fludarabine, treosulfan and melphalan in a preparative regimen for children and adolescents with Schwachman-Diamond syndrome. Bone Marrow Transplant 2007;39:143-7
   PubMed Web of Science ®Google Scholar
• Feit PW, Rastrup-Andersen N, Matagne R. Studies on epoxide formation from (2S,3S)-threitol 1,4-bismethanesulfonate. The preparation and biological activity of (2S,3S)-1,2-epoxy-3, 4-butanediol 4-methanesulfonate. J Med Chem 1970;13:1173-5
   PubMed Web of Science ®Google Scholar
• Boobis A, Rawlins M, Thomas S, Wilkins M. Treosulfan. In: Dollery C, editor, Therapeutic drugs. Churchill Livingstone, Edinburgh; 1999. p. 161-2
   Google Scholar
• Hartley JA, O'Hare CC, Baumgart J. DNA alkylation and interstrand cross-linking by treosulfan. Br J Cancer 1999;79:264-6
   PubMed Web of Science ®Google Scholar
• Matagne R. Activity of L-threitol 1,4-bismethanesulfonate on barley chromosomes in relation to chemical transformation during treatment. Mutat Res 1967;4:621-30
   Web of Science ®Google Scholar
• Park S, Anderson C, Loeber R, Interstrand and intrastrand DNA-DNA cross-linking by 1,2,3,4-diepoxybutane: role of stereochemistry. J Am Chem Soc 2005;127:14355-65
   PubMed Web of Science ®Google Scholar
• Kligerman AD, Hu Y. Some insights into the mode of action of butadiene by examining the genotoxicity of its metabolites. Chem Biol Interact 2007;166:132-9
   PubMed Web of Science ®Google Scholar
• Silverman RB. DNA and DNA-interactive agents. The organic chemistry of drug design and drug action. Academic Press, San Diego; 2004. p. 226-50
   Google Scholar
• Loeber R, Rajesh M, Fang Q, Cross-linking of the human DNA repair protein O6-alkylguanine DNA alkyltransferase to DNA in presence of 1,2,3,4-diepoxybutane. Chem Res Toxicol 2006;19:645-54
   PubMed Web of Science ®Google Scholar
• Munkelt D, Koehl U, Kloess S, Cytotoxic effects of treosulfan and busulfan against leukemic cells of pediatric patients. Cancer Chemother Pharmacol 2008;62:821-30
   PubMed Web of Science ®Google Scholar
• Meinhardt G, Dayyani F, Jahrsdorfer B, Treosulfan is an effective inducer of cell death in myeloma cell lines and primary myeloma cells from patients. Br J Haematol 2003;122:892-9
   PubMed Web of Science ®Google Scholar
• Schmidmaier R, Oellerich M, Baumgart J, Treosulfan-induced apoptosis in acute myeloid leukemia cells is accompanied by translocation of protein kinase C delta and enhanced by bryostatin-1. Exp Hematol 2004;32:76-86
   PubMed Web of Science ®Google Scholar
• Werner S, Mendoza A, Hilger RA, Preclinical studies of treosulfan demonstrate potent activity in Ewing's sarcoma. Cancer Chemother Pharmacol 2008;62:19-31
   PubMed Web of Science ®Google Scholar
• Brockmann WG, Kostotyz EL, Eick JD. Correlation of apoptotic potential of simple oxiranes with cytotoxicity. Toxicol In Vitro 2006;20:729-35
   PubMed Web of Science ®Google Scholar
• Yadavilli S, Martinez-Ceballos E, Snowden-Aikens J, Diepoxybutane activates the mitochondrial apoptotic pathway and mediates apoptosis in human lymphoblasts through oxidative stress. Toxicol In Vitro 2007;21:1429-41
   PubMed Web of Science ®Google Scholar
• Yadavilli S, Muganda PM. Diepoxybutane induces p53-mediated apoptosis in human lymphoblasts. Toxicol Appl Pharmacol 2004;195:154-65
   PubMed Web of Science ®Google Scholar
• Schlade-Bartusiak K, Rozik K, Laczmanska I, Influence of GSTT1, mEH, CYP2E1 and RAD51 polymorphism on diepoxybutane-induced SCE frequency in cultured human lymphocytes. Mutat Res 2004;558:121-30
   PubMed Web of Science ®Google Scholar
• Kim MY, Tretyakova N, Wogan GN. Mutagenesis of the supFGene by stereoisomers of 1,2,3,4-diepoxybutane. Chem Res Toxicol 2007;20:790-7
   PubMed Web of Science ®Google Scholar
• Lee DH, Kim TH, Lee SY, Mutations induced by 1,3-butadiene metabolites, butadiene diolepoxide, and 1,2,3,4-diepoxybutane at the Hprt locus in CHO-K1 cells. Mol Cells 2002;14:411-19
   PubMed Web of Science ®Google Scholar
• Neale MH, Myatt NE, Khoury GG, Comparison of the ex vivo chemosensitivity of uveal and cutaneous melanoma. Melanoma Res 2001;11:601-9
   PubMed Web of Science ®Google Scholar
• Neale MH, Myatt N, Cree IA, Combination chemotherapy for choroidal melanoma: ex vivo sensitivity to treosulfan with gemcitabine or cytosine arabinoside. Br J Cancer 1999;79:1487-93
   PubMed Web of Science ®Google Scholar
• Kopf-Maier P, Sass G. Antitumor activity of treosulfan against human breast carcinomas. Cancer Chemother Pharmacol 1992;31:103-10
   PubMed Web of Science ®Google Scholar
• Kopf-Maier P, Sass G. Antitumor activity of treosulfan in human lung carcinomas. Cancer Chemother Pharmacol 1996;37:211-21
   PubMed Web of Science ®Google Scholar
• Kopf-Maier P. The alkylator treosulfan shows activity towards human renal-cell carcinoma in vivo and in vitro. In vivo 1998;12:275-88
   PubMed Web of Science ®Google Scholar
• Feyerabend S, Feil G, Krug J, Cytotoxic effects of treosulfan on prostate cancer cell lines. Anticancer Res 2007;27:2403-8
   PubMed Web of Science ®Google Scholar
• Lanvers-Kaminsky C, Bremer A, Dirksen U, Cytotoxicity of treosulfan and busulfan on pediatric tumor cell lines. Anticancer Drugs 2006;17:657-62
   PubMed Web of Science ®Google Scholar
• Fichtner I, Becker M, Baumgart J. Antileukaemic activity of treosulfan in xenografted human acute lymphoblastic leukaemias (ALL). Eur J Cancer 2003;39:801-7
   PubMed Web of Science ®Google Scholar
• Neuber K, torn Dieck A, Blodorn-Schlicht N, Treosulfan is an effective alkylating cystostatic for malignant melanoma in vitro and in vivo. Melanoma Res 1999;9:125-32
   PubMed Web of Science ®Google Scholar
• O'Neill PA, Butt M, Eswar CV, A prospective single arm phase II study of dacarbazine and treosulfan as first-line therapy in metastatic uveal melanoma. Melanoma Res 2006;16:245-8
   PubMed Web of Science ®Google Scholar
• Keilholz U, Schuster R, Schmittel A, A clinical phase I trial of gemcitabine and treosulfan in uveal melanoma and other solid tumors. Eur J Cancer 2004;40:2047-52
   PubMed Web of Science ®Google Scholar
• Corrie PG, Shaw J, Spanswick VJ, Phase I trial combining gemcitabine and treosulfan in advanced cutaneous and uveal melanoma patients. Br J Cancer 2005;92:1997-2003
   PubMed Web of Science ®Google Scholar
• Neuber K. Treosulfan in the treatment of metastatic melanoma: from chemosensitivity testing to clinical trials. Recent Results Cancer Res 2003;161:159-79
   PubMedGoogle Scholar
• Breitbach GP, Meden H, Schmid H, Treosulfan in the treatment of advanced ovarian cancer: a randomised co-operative multicentre phase III-study. Anticancer Res 2002;22:2923-32
   PubMed Web of Science ®Google Scholar
• Vermorken JB. Second-line randomized trials in epithelial ovarian cancer. International J Gynecolo Cancer 2008;18(Suppl 1):59-66
   PubMed Web of Science ®Google Scholar
• Neuber K, Reinhold U, Deutschmann A, Second-line chemotherapy of metastatic malignant melanoma with intravenous treosulfan: a phase II multicentre trial. Melanoma Res 2003;13:81-5
   PubMed Web of Science ®Google Scholar
• Westerhof GR, Ploemacher RE, Boudewijn A, Comparison of different busulfan analogues of hematopoietic stem cell and promotion of donor type chimerism in murine bone marrow transplant recipients. Cancer Res 2000;60:5470-8
   PubMed Web of Science ®Google Scholar
• van Pel M, van Bruegel DWJG, Vos W, Towards a myeloablative regimen with clinical potential I: treosulfan conditioning and bone marrow transplantation allow induction of donor-specific tolerance for skin grafts across full MHC barriers. Bone Marrow Transplant 2003;32:15-22
   PubMed Web of Science ®Google Scholar
• Ploemacher RE, Johnson KW, Rombouts EJC, Addition of treosulfan to a nonmyeloablative conditioning regimen results in enhanced chimerism and immunologic tolerance in an experimental allogeneic bone marrow transplant model. Biol Blood Marrow Transplant 2004;10:236-45
   PubMed Web of Science ®Google Scholar
• Sjoo F, Hassan Z, Abedi-Valugerdi M, Myeloablative and immunosupressive properties of treosulfan in mice. Exp Hematol 2006;34:115-21
   PubMed Web of Science ®Google Scholar
• Giebel S, Wojnar J, Krawczyk-Kulis M, Treosulfan, cyclophosphamide and antithymocyte globulin for allogeneic hematopoietic cell transplantation in acquired severe aplastic anemia. Ann Transplant 2006;11:23-7
   PubMedGoogle Scholar
• Wachowiak J, Chybicka A, Kowalczyk J, Treosulfan-based preparative regimen for allogeneic hematopoietic stem cell transplantation in children with increased risk of conventional regimen toxicity. Blood 2005;106:500a-1a
   Google Scholar
• Wachowiak J, Grund G, Sykora KW, Treosulfan-based conditioning regimen for allogeneic transplantation in children congenital non-malignant disorders – retrospective study. Bone Marrow Transplant 2008;41(Suppl 1):S295
   Google Scholar
• Kopadze T, Dehmel T, Mylius HA, Treosulfan impedes the migration of immunocompetent cells. J Neurol 2007;254:1457-8
   PubMed Web of Science ®Google Scholar
• Weissert R, Wiendl H, Pfrommer H, Action of treosulfan in myelin-oligodendrocyte-glycoprotein-induced experimental autoimmune encephalomyelitis and human lymphocytes. J Neuroimmunol 2003;144:28-37
   PubMed Web of Science ®Google Scholar
• Wiendl H, Kieseier BC, Weissert R, Treatment of active secondary progressive multiple sclerosis with treosulfan. J Neurol 2007;254:884-9
   PubMed Web of Science ®Google Scholar
• Atzpodien J, Terfloth K, Fluck M, Reitz M. Cisplatin, gemcitabine and treosulfan is effective in chemotherapy-pretreated relapsed stage IV uveal melanoma patients. Cancer Chemother Pharmacol 2008;62:685-8
   PubMed Web of Science ®Google Scholar
• Cree IA, Neale MH, Reinhold U, Kurbacher CM. Treosulfan and gemcitabine. J Cancer Res Clin Oncol 2005;131:329-30
   PubMed Web of Science ®Google Scholar
• Breidenbach M, Rein D, Schondorf T, Hematological side-effect profiles of individualized chemotherapy regimen for recurrent ovarian cancer. Anticancer Drugs 2003;14:341-6
   PubMed Web of Science ®Google Scholar
• Wick W, Stock J, Seyfried J, CD95/CD95 ligand-independent potentiation of treosulfan cytotoxicity by BSO in malignant glioma cells in vitro and in vivo. Int J Oncol 2002;21:213-20
   PubMed Web of Science ®Google Scholar
• Baumann P, Mandl-Weber S, Volkl A, Dihydroorotate dehydrogenase inhibitor A771726 (leflunomide) induces apoptosis and diminishes proliferation of multiple myeloma cells. Mol Cancer Ther 2009;8:366-75
   PubMed Web of Science ®Google Scholar
• Turci R, Sottani C, Ronchi A, Minoia C. Biological monitoring of hospital personnel occupationally exposed to antineoplastic agents. Toxicol Lett 2002;134:57-64
   PubMed Web of Science ®Google Scholar
• Harstrick A, Wilke H, Klaassen U, A phase I dose escalation trial of intravenous treosulfan in refractory cancer. Onkologie 1996;19:153-6
   Web of Science ®Google Scholar
• Hilger RA, Gabriele J, Oberhoff C, Investigation of bioavailability and pharmacokinetics of treosulfan capsules in patients with relapsed ovarian cancer. Cancer Chemother Pharmacol 2000;45:483-8
   PubMed Web of Science ®Google Scholar
• Koenigsmann M, Mohren M, Jentsch-Ullrich K, Conditioning regimens. High-dose treosulfan in patients with relapsed or refractory high-grade lymphoma receiving tandem autologous blood stem cell transplantation. Bone Marrow Transplant 2004;34:477-83
   PubMed Web of Science ®Google Scholar
• Bojko P, Scheulen ME, Hilger R, High-dose chemotherapy with peripheral blood stem cell transplantation for patients with advanced ovarian cancer. J Cancer Res Clin Oncol 2001;127:243-50
   PubMed Web of Science ®Google Scholar
• Wagner H, Baumgart J, Andreesen R, Dose-escalation of treosulfan in a high-dose-protocol: a classical alkylating agent new in high-dose combination chemotherapy. Proc Am Soc Clin Oncol 2000;19: abstract 208
   Google Scholar
• Baynes R, Parchment R, Dansey R, Phase I evaluation of high dose melphalan, DTIC and treosulfan (MDT) in previously treated metastatic breast and ovarian cancer. Proc Am Soc Clin Oncol 2000;19: abstract 585
   Google Scholar
• Bock J, Doenitz A, Andreesen R, Pericarditis after high-dose chemotherapy: more frequent than expected? Onkologie 2006;29:321-4
   PubMed Web of Science ®Google Scholar
• Bojko P, Hilger RA, Ruehm SG, Post-transplant complications. Femoral head necrosis in three patients with relapsed ovarian cancer receiving high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2003;31:487-91
   PubMed Web of Science ®Google Scholar
• Shimoni A, Hardan I, Shem-Tov N, Fludarabine and treosulfan: a novel modified myeloablative regimen for allogeneic hematopoietic stem-cell transplantation with effective antileukemia activity in patients with acute myeloid leukemia and myelodysplastic syndrome. Leuk Lymphoma 2007;48:2352-9
   PubMed Web of Science ®Google Scholar
• Kroger N, Shimoni A, Zabelina T, Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS). Bone Marrow Transplant 2006;37:339-44
   PubMed Web of Science ®Google Scholar
• Holowiecki J, Giebel S, Wojnar J, Treosulfan and fludarabine low-toxicity conditioning for allogeneic haematopoietic stem cell transplantation in chronic myeloid leukemia. Br J Haematol 2008;142:284-92
   PubMed Web of Science ®Google Scholar
• Schmidt-Hieber M, Blau IW, Tenschel R, Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplant 2007;39:389-96
   PubMed Web of Science ®Google Scholar
• Baronciani D, Rambaldi A, Iori AP, Treosulfan/fludarabine as an allogeneic stem cell transplant conditioning regimen for high-risk patients. Am J Hematol 2008;83:717-20
   PubMed Web of Science ®Google Scholar
• Bernardo ME, Zecca M, Piras E, Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in patients with thalassaemia major. Br J Haematol 2008;143:548-51
   PubMed Web of Science ®Google Scholar
• Greystoke B, Bonanomi S, Carr TF, Treosulfan-containing regimens achieve high rates of engraftment associated with low transplant morbidity and mortality in children with non-malignant disease and significant co-morbidities. Br J Haematol 2008;142:257-62
   PubMed Web of Science ®Google Scholar
• Meissner B, Borkhardt A, Dilloo D, Relapse, not regimen-related toxicity, was the major cause of treatment failure in 11 children with Down syndrome undergoing haematopoietic stem cell transplantation for acute leukemia. Bone Marrow Transplant 2007;40:945-9
   PubMed Web of Science ®Google Scholar
• Welsh J, Stuart JFB, Soukop M, The pharmacokinetics of oral and iv treosulfan. Br J Cancer 1982;46:467
   Web of Science ®Google Scholar
• Hilger RA, Baumgart J, Scheulen ME, Pharmacokinetics of treosulfan in a myeloablative combination with cyclophosphamide prior to allogeneic hematopoietic stem cell transplantation. Int J Clin Pharmacol Ther 2004;42:654-5
   PubMedGoogle Scholar
• Muller H, Hilger R. Curative and palliative aspects of regional chemotherapy in combination with surgery. Support Care Cancer 2003;11:1-11
   PubMed Web of Science ®Google Scholar
• Glowka FK, Karazniewicz-Lada M, Grund G, Wachowiak J. Determination of treosulfan in plasma and urine by HPLC with refractometric detection; pharmacokinetics studies in children undergoing myeloablative treatment prior to haematopoietic stem cell transplantation. J Chromatogr B 2007;850:569-74
   PubMed Web of Science ®Google Scholar
• Glowka FK, Karazniewicz-Lada M, Grund G, Pharmacokinetics of high-dose i.v. treosulfan in children undergoing treosulfan-based preparative regimen for allogeneic hematopoietic SCT. Bone Marrow Transplant 2008;42:S67-70
   PubMed Web of Science ®Google Scholar
• Drabko K, Zawitkowska-Klaczynska J, Wojcik B, Megachemotherapy followed by autologous stem cell transplantation in children with Ewing's sarcoma. Pediatr Transplant 2005;9:618-21
   PubMed Web of Science ®Google Scholar
• Blau IW, Schmidt-Hieber N, Leschinger N, Engraftment kinetics and hematopoietic chimerism after reduced-intensity conditioning with fludarabine and treosulfan before allogeneic stem cell transplantation. Ann Hematol 2007;86:583-9
   PubMed Web of Science ®Google Scholar
• Markiewicz M, Wojciechowska M, Wylezol I, First two successful unrelated bone marrow transplantations for paroxysmal nocturnal hemoglobinuria in Poland. Ann Transplant 2005;10:26-30
   PubMedGoogle Scholar
• Fruehauf S, Buss EC, Topaly J, Myeloablative conditioning in myelofibrosis using i.v. treosulfan and autologous peripheral blood stem cell transplantation with high doses of CD34+ cells results in hematologic responses – follow-up of three patients. Haematologica 2005;90:17-20
   Google Scholar
• Klaudel-Dreszler MA, Kalwak K, Kurenko-Deptuch M, Treoulfan-based conditioning regimen in a second matched unrelated peripheral blood stem cell transplantation for a pediatric patient with CGD and invasive aspergillosis, who experienced initial graft failure after RIC. Int J Hematol 2009;90:571-5
   PubMed Web of Science ®Google Scholar
• Shimoni A, Rand A, Shem-Tov N, Allogeneic hematopoietic stem-cell transplantation using fludarabine/treosulfan conditioning regimen compared with busulfan-based myeloablative and reduced-intensity conditioning in patients with AML and MDS; relative outcomes depend on disease status at transplantation [abstract 3358]. 51st ASH Annual Meeting and Exposition; 5 – 8 December 2009
   Google Scholar
• EMEA/COMP/371/04; London, 22 November 2004 Available from: http://www.ema.euro-pa.eu/pdfs/human/comp/opinion/037104en.pdf [Last accessed 5 May 2010]
   Google Scholar
• Wachowiak J, Chybicka A, Kowalczyk JR, Treosulfan-based preparative regimen for second hematopoietic stem cell transplantation in children with advanced hematologic malignancies. Bone Marrow Transplant 2005;35(Suppl 1):S96-7
   Google Scholar
• Nath CE, Shaw PJ. Busulphan in blood and marrow transplantation: dose, route, frequency and role of therapeutic drug monitoring. Curr Clin Pharmacol 2007;2:75-91
   PubMedGoogle Scholar
• Hoy SM, Lyseng-Williamson KA. Intravenous busulfan in the conditioning treatment of pediatric patients prior to hematopoietic stem cell transplantation. Pediatr Drugs 2007;9:271-8
   PubMedGoogle Scholar
• European Medicines Agency – Human Medicines – Busilvex. Busilvex – EPAR: Product Information. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000472/human_med_000681.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d124 [Last accessed 2 August 2010]
   Google Scholar
• IV BUSULFEX (busulfan) Injection. Full prescribing information. Available from: http://www.ivbusul-fex.com/0608L-0078A_Otsuka_ IVBUSULFEX_Injection_PI.pdf [Last accessed 2 August 2010]
   Google Scholar
• Bartelink IH, Bredius RGM, Ververs TT, Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2008;14:88-98
   PubMed Web of Science ®Google Scholar
• Schechter T, Finkelstein Y, Doyle J, Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007;13:307-14
   PubMed Web of Science ®Google Scholar
• Nishikawa T, Okamoto Y, Tanabe T, Unexpectedly high AUC levels in a child who received intravenous busulfan before stem cell transplantation. Bone marrow Transplant 2010;45:602-4
   PubMed Web of Science ®Google Scholar
• Buchali A, Feyer P, Groll J, Immediate toxicity during fractionated total body irradiation as conditioning for bone marrow transplantation. Radiother Oncol 2000;54:157-62
   PubMed Web of Science ®Google Scholar
• Bond JA, Medinsky MA. Insights into the toxicokinetics and toxicodynamics of 1,3-butadiene. Chem Biol Interact 2001;135-136:599-614
   PubMed Web of Science ®Google Scholar